Share Name Share Symbol Market Type Share ISIN Share Description
Amryt Pharma Plc LSE:AMYT London Ordinary Share GB00BKLTQ412 ORD 6P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 123.00 121.00 125.00 123.00 123.00 123.00 12,569 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 13.0 -23.1 -8.4 - 190

Amryt Pharma Share Discussion Threads

Showing 5251 to 5274 of 5400 messages
Chat Pages: 216  215  214  213  212  211  210  209  208  207  206  205  Older
DateSubjectAuthorDiscuss
06/11/2019
13:07
LOL, purple11. Don't forget to wake me up! "So wake me up when it's all over When I'm wiser and I'm older"
papillon
06/11/2019
11:31
nite pappy
purple11
06/11/2019
11:30
Back to sleep, until the next RNS.
papillon
05/11/2019
22:37
https://www.irishtimes.com/business/health-pharma/dublin-pharma-company-amryt-grows-sales-almost-20-1.4072998?mode=amp
tiananmen
05/11/2019
19:56
"It looks undervalued at less than 2 x full year sales. Cash helps but will get spent." Don't forget AMYT has debt, waterloo. The amount of debt must also be acknowledged in any attempt at valuing AMYT. Don't forget we've already had a broker note, waterloo. Stiffel's valuation dated 1st October. That was first posted by Bronxville on the lse bb and copied by me onto this bb last week (post 5087). Stiffel reckon … … … "that revenue-generative orphan drug companies trade at 8.8-times historic earnings." Seems rather fanciful to me, but even 4 x historic earnings valuation gives a 240p AMYT share price
papillon
05/11/2019
19:24
£zillions........! Sorry, don’t have the expertise - guess that makes me a gambler and not an investor! At least I’m a very patient gambler.... Fingers very firmly crossed!
bazworth
05/11/2019
18:55
Well at least they are not free options but have a strike price of £1.21. Makes them as keen as shareholders to see the share price climb. Would love to see a broker note. Any around? It looks undervalued at less than 2 x full year sales. Cash helps but will get spent. Hopefully the combined entity has a reasonable cost base. Any thoughts on appropriate valuation based on revenue now it's more visible?
waterloo01
05/11/2019
18:48
Hope it’s positive!
bazworth
05/11/2019
18:39
Timing of the options grant is telling in my opinion
alphabravo321
05/11/2019
18:23
Big options grant for the lads
alphabravo321
05/11/2019
17:17
Big buy just after 4pm. 106,352 @ 122.50p. Cost £130.28k.
papillon
05/11/2019
14:23
ADVFN have blocked the link I posted in my previous post because of the word proactive in the link. So here is the YouTube link to the same video and Rory Nealon interview today. https://www.youtube.com/watch?v=dSxt_45OOPo&t=33s In the interview, alphabravo, Rory Nealon just states that a Nasdaq listing is under consideration. No firm date. No confirmation it will happen within the 90 day period since 24th September.
papillon
05/11/2019
14:05
I am sticking with the commitment in the admission doc of seeking a Nasdaq listing within 90 days of deal closure which was Sep 24th.
alphabravo321
05/11/2019
13:41
jupiternmars Posts: 1,286 Price: 121.50 No Opinion Rory Nealon - Proactive Today 13:16 [...] >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> It's well worth watching the video and listening to Rory Nealon being interviewed. The Nasdaq listing is commented on at the end of the interview by Nealon when questioned about it. It doesn't appear to be imminent.
papillon
05/11/2019
12:39
Good sales figures, waterloo, but disappointed with the lack of news on the Nasdaq listing and a lower cash balance than I expected (US$61.2m = £47.44m at 31st October). Combined sales revenue of US$113.1m for the first 9 months of 2019 implies combined sales revenue of US$150.8m for the whole of 2019. That's inline with market expectations.
papillon
05/11/2019
12:14
Yes noticeably absent. No idea why.
waterloo01
05/11/2019
12:10
No mention of the Nasdaq listing in today's RNS. Cash balance of US$61.2m (£47.44m) @ 31st October.
papillon
05/11/2019
11:12
surprised at the lack of trades here. Any broker notes or updates?
gucci
05/11/2019
07:35
Results look excellent. Continued growth.
waterloo01
04/11/2019
13:12
The following is from the AMYT RNS dated 15/3/2018: "Potential competitors working in the area of gene therapy in EB are working with viral vectors to deliver collagen VII to the cell. The patented technology which Amryt has exclusively licenced from UCD involves the use of a novel gene delivery mechanism using HPAE polymer technology. If successful, this will eliminate the requirement for viruses as delivery vectors and provides a potential competitive advantage to Amryt. Recently Krystal Biotech Inc, a US company completed a successful listing on NASDAQ in September 2017, with a topical gene therapy for EB using a viral vector." Krystal Biotech (NASDAQ-CM: KRYS) has a Mkt Cap of US$732.5m (sp US$42.34). Looking at their latest a/c's KRYS doesn't have any sales revenue, but does have US$186.6m of cash and cash equivalents plus US$8.9m of short term investments. Going by the Mkt Cap of KRYS I believe that the AMYT share price should fly upwards when it lists on NASDAQ. KRYS has more than twice the cash of AMYT, but AMYT has over US$130m of sales revenue which KRYS does not have. However KRYS, unlike AMYT, has no debt. Post edited @ 2:50pm 4/11/2019
papillon
04/11/2019
11:00
9 month results to 30th September to be issued tomorrow!! They are getting ready for Nasdaq listing by issuing quarterly results.
papillon
02/11/2019
10:24
This is quite subjective... whether the Ph3 results are a great success. Firstly, there are no current approved therapies for EB, so from this perspective ANY new product approved could be considered a great success. However, we can see from previous studies with Episalvan that efficacy is in the region of 10% (placebo-adjusted). The interim results of EASE resulted in the DSMB recommending an increase in study size to about 230 patients. This could have been due to 2 likely reasons:- 1) The observed treatment difference between episalvan and placebo (during interim analysis) was smaller than expected. 2) The variability in the Primary Endpoint was higher than expected. Hence, my personal prediction is that EASE will be positive, but show efficacy around 7-8%. What does this mean for Amryt? Episalvan will likely get approval by FDA/EMA but their assessment will be that Episalvan has modest efficacy. The drug will have its uses in the EB population, especially to alleviate symptoms. It will be a step in the right direction for EB patients, who will have a first approved product. Episalvan however will not have potent efficacy circa 20-30% reduction in EB lesions. It certainly will not be curative, unlike certain EB gene therapies in clinical development. For potential curative effects, we will have to wait for AP103, their gene-based therapy.
diamondstar1
01/11/2019
19:18
"but don't expect great results from the phase 3" why ?
delta0091
01/11/2019
19:03
That's certainly possible but any. They do have many more rules but any delay won't be by AMYT choice IMO
waterloo01
Chat Pages: 216  215  214  213  212  211  210  209  208  207  206  205  Older
Your Recent History
LSE
AMYT
Amryt Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200217 17:03:38